Over 170 carefully curated, well-characterized patient-derived xenograft tumor models are available for use in your facility, or use Horizon’s comprehensive preclinical in vivo efficacy service.
Tumor heterogeneity is a challenge in cancer research and drug development. Examination of cancer cell lines does not offer a comprehensive view of a tumor or tumor microenvironment. This is where it can be helpful to examine a patient derived xenograft (PDX) model of tumors.
Horizon Discovery has strategically partnered with exceptional institutions to provide access to the best, most characterized patient derived xenograft models for breast cancers and melanomas.
With Washington University School of Medicine in St. Louis, Missouri, we exclusively offer the highly-characterized WHIM (Washington University Human-in-Mouse) breast cancer PDX collection.
More recently, we have partnered with The Wistar Institute of Anatomy and Biology in Philadelphia, Pennsylvania, to exclusively offer a subset of their large collection of highly characterized melanoma PDX models.
All of our PDX models are also available as cells in suspension or as in-vivo models with implanted cells.
Our comprehensive pre-clinical efficacy service ensures that all the hard work is done for you, to the highest standards.
Patient Derived Xenograft models are typically implanted as dissociated cells or tumor fragments into immunodeficient mouse models which may then be used for in vivo efficacy studies, allowing you to accelerate your oncology research or drug discovery and development programs, including applications for:
Horizon offers our cancer model collections as ungrafted PDX suspensions or as comprehensive in vivo efficacy studies.
For services, simply provide us with your test articles, and our team of experienced scientists will demonstrate their effect on PDX grown in immunodeficient mice. Horizon’s offerings and capabilities include: